Medical News

RSS

Virtua achieves significant clinical milestone in the adoption of electronic health records

Today, Siemens Healthcare has announced that Virtua, a multi-hospital healthcare system, has achieved a significant clinical milestone in the adoption of electronic health records.

27 Aug 2012

Pristine Solutions acquires Eaton Scientific Systems

Pristine Solutions, Inc. is pleased to announce that the Company has completed the acquisition of Eaton Scientific Systems, Ltd., a biomedical product development company focused on women's health solutions.

27 Aug 2012

Blockade Medical's Barricade Coil System successfully treats patients with aneurysms

Blockade Medical announced today the first patients have been treated with the Barricade Coil System. Patients treated with the Barricade Coil System presented with diverse cerebral aneurysms.

27 Aug 2012

Women with severe aortic stenosis less likely to die following TAVI

Women with severe aortic stenosis are 40% less likely to die after transcatheter aortic valve implantation (TAVI) than men, reveals the latest data from the largest study to date of gender differences in outcomes after TAVI.

27 Aug 2012

Merz acquires CUVPOSA oral solution to treat children with cerebral palsy

Merz, Inc. today announced the acquisition of CUVPOSA (glycopyrrolate) oral solution for pediatric chronic severe drooling associated with neurologic conditions such as cerebral palsy.

27 Aug 2012

BioTime amends license agreement with University of Utah for HyStem technology

BioTime, Inc. announced that the company has amended its license from the University of Utah to expand the field of use for which BioTime is licensed to produce and market products covered by the core patents underlying HyStem technology.

27 Aug 2012

Tris Pharma joins Perrigo to launch first ever store brand ER liquid cough/cold product

Perrigo Company and Tris Pharma, Inc. today announced the commercial launch of a major new store brand product. The new product is equivalent to Delsym extended–release oral liquid suspension containing dextromethorphan polistirex and will be marketed under major U.S. retailer and wholesalers' store brands or own label brands.

27 Aug 2012

Political cartoon: 'Opening Act?'

Kaiser Health News provides a fresh take on health policy developments with "Opening Act?" by John Deering.

27 Aug 2012

Diaverum plans to increase peritoneal dialysis use among patients with ESRD

Diaverum, one of the world's leading renal care providers, is planning to give more patients the possibility to be treated with peritoneal dialysis to increase their quality of life.

27 Aug 2012

IXYS board authorizes additional stock repurchase program

IXYS Corporation announced today that its Board of Directors has authorized an additional stock repurchase program of up to 1,000,000 shares of its common stock, or approximately 3% of the Company's approximately 31 million shares of common stock currently outstanding.

27 Aug 2012

Insulin glargine retards progression of atherosclerosis in high-risk people

A sub-study of the Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial, designed to investigate the effect of insulin glargine and omega-3 fatty acids on atherosclerosis progression, has found that, compared to standard care, only insulin glargine (a long-acting insulin) had a "modest" statistically non-significant reducing effect on the primary outcome of rate of change in maximum carotid intima media thickness (CIMT) at 12 carotid sites.

27 Aug 2012

Academic Urology signs new contract with Independence Blue Cross

Academic Urology, the largest urology specialty medical group in Pennsylvania, announced today that it has signed a new contract with Independence Blue Cross (IBC).

27 Aug 2012

Renal denervation leads to better outcomes than standard drug treatment in patients with AHF

Renal denervation leads to better outcomes than standard drug treatment in patients with advanced heart failure, according to research presented at ESC Congress 2012. The results of the Olomouc I pilot study were presented by Dr Miloš Táborský from the University Hospital Olomouc.

27 Aug 2012

Mallinckrodt receives FDA approval for 32 mg tablet strength of EXALGO

The U.S. Food and Drug Administration (FDA) has notified Mallinckrodt, the pharmaceuticals business of Covidien, that it has approved a 32 mg tablet strength of EXALGO (hydromorphone HCI) Extended-Release Tablets (CII) for opioid-tolerant patients with moderate-to-severe chronic pain requiring continuous around-the-clock opioid analgesia for an extended period of time.

27 Aug 2012

Bode launches Rapid DNA Service to provide near real-time analysis

The Bode Technology Group, Inc. (Bode), a leading provider of innovative forensic DNA services, announced today the launch of their Rapid DNA Service to provide near real-time DNA analysis.

27 Aug 2012

BD announces acquisition of Sirigen

BD, a leading global medical technology company, announced today that it has acquired Sirigen Group Limited, a developer of unique polymer dyes that are used in flow cytometry and can be applied to other technologies.

From BD (Becton, Dickinson and Company) 27 Aug 2012

Taiwan approves RBC Life Sciences' Stem-Kine for importation and sale

RBC Life Sciences, Inc. announced today that the Company's stem cell supplement, Stem-Kine, has been approved for importation and sale in Taiwan. Stem-Kine is marketed in Taiwan under the name SK Plus.

27 Aug 2012

Update on Merck's development programs for vorapaxar, ER niacin/laropirprant and anacetrapib

Merck today provided an update on the development programs for vorapaxar, extended release niacin/laropirprant (MK524A, Tredaptive) and anacetrapib in association with the European Society of Cardiology (ESC) meeting in Munich.

27 Aug 2012

Healthy foods consumed more often by the wealthy than poor

Healthy foods such as fruits and vegetables, proteins and non-saturated fats are consumed more often by the wealthy while poorer people consume more carbohydrates, concludes a new study involving people from 17 countries.

27 Aug 2012

Additional data from Auxilium XIAFLEX phase III studies on Peyronie's disease

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, announced that additional data will be presented from its IMPRESS (The Investigation for Maximal Peyronie's Reduction Efficacy and Safety Studies) trials, the phase III studies that assessed XIAFLEX (collagenase clostridium histolyticum or CCH), a novel, in-office, first-in-class biologic therapy for the potential treatment of Peyronie's disease (PD).

27 Aug 2012